Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finite Element Analysis of Maxillary Overdentures Supported by Two, Three, and Four Implants.

Bioengineering (Basel, Switzerland)·2025
Same author

Multiorgan Peripheral T-Cell Lymphoma Presenting as Isolated Cardiomyopathy.

JACC. Case reports·2025
Same author

Mitochondrial respiratory activity and DNA damage in peripheral blood mononuclear cells in borderline personality disorder.

Psychological medicine·2025
Same author

Lipid Monolayers Adsorbing mRNA as Models for mRNA Enclosed in Lipid Nanoparticles for Transfection.

Langmuir : the ACS journal of surfaces and colloids·2025
Same author

iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products.

Molecular pharmaceutics·2025
Same author

A Model-Based Evaluation of Noninvasive Biomarkers to Reflect Histological Nonalcoholic Fatty Liver Disease Scores.

Pharmaceutical research·2024

Related Experiment Video

Updated: May 17, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

A pharmacokinetic simulation tool for inhaled corticosteroids.

Benjamin Weber1, Guenther Hochhaus

  • 1Department of Pharmaceutics, College of Pharmacy, Center of Pharmacometrics and Systems Pharmacology, University of Florida, 1600 SW Archer Road, P3-33, Gainesville, FL 32610, USA.

The AAPS Journal
|November 10, 2012
PubMed
Summary

This study presents a new pharmacokinetic model for inhaled corticosteroids (ICS), accounting for lung physiology and formulation. A simulation tool, ICSpkTS, is also provided for PK trial analysis.

More Related Videos

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
15:04

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Related Experiment Videos

Last Updated: May 17, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
15:04

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Area of Science:

  • Pharmacokinetics
  • Pharmacodynamics
  • Drug Development

Background:

  • Inhaled drug pharmacokinetics are complex, influenced by physiological, formulation, and patient factors.
  • Understanding systemic absorption and lung disposition is crucial for inhaled corticosteroids (ICS).

Purpose of the Study:

  • To develop a compartmental model for inhaled corticosteroid (ICS) fate after administration.
  • To create a simulation tool for pharmacokinetic (PK) trials of ICS.

Main Methods:

  • A compartmental model was developed, incorporating mucociliary clearance, central/peripheral lung regions, and dual absorption routes (lung and GI tract).
  • The 'ICSpkTS' R package was created for simulating PK trials of hypothetical and commercial ICS.
  • Simulations were performed for budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide.

Main Results:

  • The compartmental model accurately describes ICS fate, considering inter- and intra-subject variability.
  • Simulated PK data and parameters closely matched literature data for four commercial ICS.
  • The ICSpkTS package demonstrated suitability for exploring parameter effects on PK behavior.

Conclusions:

  • The developed compartmental model provides a robust framework for understanding inhaled corticosteroid pharmacokinetics.
  • The ICSpkTS R package serves as a valuable, freely available tool for PK trial simulation and analysis.
  • This model and tool can be adapted for other inhaled medications, advancing drug development.